| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Cimaterol, a stimulant, a fat burner, is a beta-adrenoceptor agonist that work with beta-adrenoceptors (pEC 50 s=8.13, 8.78, and 6.62 for human β1, β2, and β3, respectively) and leads to increased weight gain in the skeletal muscle. It has been shown to stimulate lipolysis.
| ln Vitro |
Two myogenic cell lines (L6 and G8-1) treated with the β-adrenergic agonist Cimaterol for six hours showed a 12% increase in protein synthesis. Citameterol's EC50 (about 5 nM) for inducing protein synthesis is in line with its Kd of 26 nM for binding to the L6 beta receptor [2]. During the C2C12 cell proliferation phase, citerol promotes the build-up of intracellular cAMP and boosts muscle cell viability. Following drug exposure, cAMP concentrations significantly rise in response to imidaterol (1 µM) [3].
|
|---|---|
| ln Vivo |
In ob/ob mice, calceum promotes the growth of skeletal muscle [1]. At dietary doses of 0.25 mg/kg, cititerrol administered to finishing pigs can marginally enhance daily weight growth [4].
|
| Cell Assay |
Cell Proliferation Assay[3]
Cell Types: Mouse C2C12 Myoblasts Tested Concentrations: 0.1 and 1 µM Incubation Duration: 8 Days Experimental Results: On Days 1, 2 and 3, treated cells appeared compared to untreated cells Rapid proliferation and increase in absorbance From day 5 to day 8, the trend reversed, and the absorbance of control cells was Dramatically greater than that of treated cells. |
| Animal Protocol |
Animal/Disease Models: 150 crossbred pigs (55 kg) [4]
Doses: Corn-soybean meal based diet (0.65% lysine) supplemented with 0, 0.25 and 0.5 mg/kg Route of Administration: Experimental Results: Pig Feed Patients fed 0.25 mg/kg had a 6.8%, 7.7% and 13.5% reduction in 10th rib fat depth and a 13.5% reduction in P2 fat depth in patients who had been off medication for 1 day compared with patients who were off medication for 3 or 5 days or fed 0 mg/dose. 11.1%, 6.1% and 13.3%. kg cimaterol diet (control), respectively. Resulting in higher Warner-Bratzler shear values and changing the saturation ratio of some long-chain fatty acids at 0.5 mg/kg. |
| References |
[1]. H C Walker, et al. Effects of cimaterol, a beta-adrenergic agonist, on energy metabolism in ob/ob mice. Am J Physiol. 1988 Dec;255(6 Pt 2):R952-60.
[2]. J M Harper, et al. The effects of beta agonists on muscle cells in culture. Domest Anim Endocrinol. 1990 Oct;7(4):477-84. [3]. Boimpoundi Eunice Flavie Ouali, et al. Beta-agonist drugs modulate the proliferation and differentiation of skeletal muscle cells in vitro. Biochem Biophys Rep. 2021 May 18;26:101019. [4]. W R Walker, et al. Evaluation of cimaterol for finishing swine including a drug withdrawal period. J Anim Sci. 1989 Jan;67(1):168-76. |
| Additional Infomation |
2-amino-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzonitrile is a member of benzenes and a nitrile.
See also: 1-Isopropylpiperidin-4-ol (annotation moved to). |
| Molecular Formula |
C12H17N3O
|
|---|---|
| Molecular Weight |
219.2829
|
| Exact Mass |
219.137
|
| CAS # |
54239-37-1
|
| Related CAS # |
Cimaterol-d7;1228182-44-2
|
| PubChem CID |
2755
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
436.6±45.0 °C at 760 mmHg
|
| Melting Point |
162-164ºC
|
| Flash Point |
217.8±28.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.573
|
| LogP |
0.77
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
16
|
| Complexity |
258
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C([H])(C1C([H])=C([H])C(=C(C#N)C=1[H])N([H])[H])C([H])([H])N([H])C([H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
BUXRLJCGHZZYNE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H17N3O/c1-8(2)15-7-12(16)9-3-4-11(14)10(5-9)6-13/h3-5,8,12,15-16H,7,14H2,1-2H3
|
| Chemical Name |
2-amino-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzonitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5604 mL | 22.8019 mL | 45.6038 mL | |
| 5 mM | 0.9121 mL | 4.5604 mL | 9.1208 mL | |
| 10 mM | 0.4560 mL | 2.2802 mL | 4.5604 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA